Literature DB >> 23562298

Supplementation with a powdered blend of PUFAs normalizes DHA and AA levels in patients with PKU.

Judith J Jans1, Monique G M de Sain-van der Velden, Peter M van Hasselt, Dorine T A M van den Hurk, Frederic M Vaz, Gepke Visser, Nanda M Verhoeven-Duif.   

Abstract

UNLABELLED: Patients with phenylketonuria (PKU) have a poor LC-PUFA status and require supplementation. The objective of this study was to evaluate the LC-PUFA status of PKU patients supplemented with fish oil or the fatty acid supplement KeyOmega. Plasma and erythrocyte docosahexaenoic acid (DHA) and arachidonic acid (AA) levels were determined in 54 patients (1-18.5years of age) with confirmed PKU. The influence of supplementation with fish oil versus KeyOmega, a powdered blend of DHA and AA, on LC-PUFA status was investigated and compared to the status in samples obtained from unsupplemented patients. Differential effects on LC-PUFA status were observed upon suppletion with fish oil versus KeyOmega. Whereas supplementation with fish oil increased the level of DHA, the AA concentration did not increase to normal values in these patients. In contrast, both DHA and AA levels increased and reached reference values upon supplementation with KeyOmega. IN
CONCLUSION: these results indicate that KeyOmega offers additional benefit over fish oil since both AA and DHA status are normalized in PKU patients supplemented with KeyOmega.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562298     DOI: 10.1016/j.ymgme.2013.03.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  Omega-3 fatty acid supplementation can prevent changes in mitochondrial energy metabolism and oxidative stress caused by chronic administration of L-tyrosine in the brain of rats.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Maria L Gomes; Bruna K Ferreira; Patricia F Schuck; Gustavo C Ferreira; Felipe Dal-Pizzol; Jade de Oliveira; Giselli Scaini; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-04-04       Impact factor: 3.584

3.  Effects of omega-3 fatty acids supplementation on inflammatory parameters after chronic administration of L-tyrosine.

Authors:  Rafaela Antonini; Giselli Scaini; Monique Michels; Mariane B D Matias; Patrícia F Schuck; Gustavo C Ferreira; Jade de Oliveira; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-12-11       Impact factor: 3.584

4.  Modulation of Adipocyte Differentiation and Proadipogenic Gene Expression by Sulforaphane, Genistein, and Docosahexaenoic Acid as a First Step to Counteract Obesity.

Authors:  Veronica Valli; Katharina Heilmann; Francesca Danesi; Alessandra Bordoni; Clarissa Gerhäuser
Journal:  Oxid Med Cell Longev       Date:  2018-02-07       Impact factor: 6.543

5.  Metabolomic Insights into the Nutritional Status of Adults and Adolescents with Phenylketonuria Consuming a Low-Phenylalanine Diet in Combination with Amino Acid and Glycomacropeptide Medical Foods.

Authors:  Bridget M Stroup; Denise M Ney; Sangita G Murali; Frances Rohr; Sally T Gleason; Sandra C van Calcar; Harvey L Levy
Journal:  J Nutr Metab       Date:  2017-12-31

6.  Characterization of Choline Nutriture among Adults and Children with Phenylketonuria.

Authors:  Meriah S Schoen; Usha Ramakrishnan; Jessica A Alvarez; Thomas R Ziegler; Xiangqin Cui; Rani H Singh
Journal:  Nutrients       Date:  2022-09-29       Impact factor: 6.706

7.  Is cytotoxicity a determinant of the different in vitro and in vivo effects of bioactives?

Authors:  Mattia Di Nunzio; Veronica Valli; Lidia Tomás-Cobos; Teresa Tomás-Chisbert; Lucía Murgui-Bosch; Francesca Danesi; Alessandra Bordoni
Journal:  BMC Complement Altern Med       Date:  2017-09-07       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.